Your browser doesn't support javascript.
loading
Genetic Mechanisms of Immune Evasion in Colorectal Cancer.
Grasso, Catherine S; Giannakis, Marios; Wells, Daniel K; Hamada, Tsuyoshi; Mu, Xinmeng Jasmine; Quist, Michael; Nowak, Jonathan A; Nishihara, Reiko; Qian, Zhi Rong; Inamura, Kentaro; Morikawa, Teppei; Nosho, Katsuhiko; Abril-Rodriguez, Gabriel; Connolly, Charles; Escuin-Ordinas, Helena; Geybels, Milan S; Grady, William M; Hsu, Li; Hu-Lieskovan, Siwen; Huyghe, Jeroen R; Kim, Yeon Joo; Krystofinski, Paige; Leiserson, Mark D M; Montoya, Dennis J; Nadel, Brian B; Pellegrini, Matteo; Pritchard, Colin C; Puig-Saus, Cristina; Quist, Elleanor H; Raphael, Ben J; Salipante, Stephen J; Shin, Daniel Sanghoon; Shinbrot, Eve; Shirts, Brian; Shukla, Sachet; Stanford, Janet L; Sun, Wei; Tsoi, Jennifer; Upfill-Brown, Alexander; Wheeler, David A; Wu, Catherine J; Yu, Ming; Zaidi, Syed H; Zaretsky, Jesse M; Gabriel, Stacey B; Lander, Eric S; Garraway, Levi A; Hudson, Thomas J; Fuchs, Charles S; Ribas, Antoni.
Afiliação
  • Grasso CS; Department of Medicine, Division of Hematology-Oncology, University of California, Los Angeles, and the Jonsson Comprehensive Cancer Center, Los Angeles, California. cgrasso@mednet.ucla.edu.
  • Giannakis M; Parker Institute for Cancer Immunotherapy, San Francisco, California.
  • Wells DK; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
  • Hamada T; Broad Institute of MIT and Harvard, Cambridge, Massachusetts.
  • Mu XJ; Parker Institute for Cancer Immunotherapy, San Francisco, California.
  • Quist M; Department of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Nowak JA; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
  • Nishihara R; Broad Institute of MIT and Harvard, Cambridge, Massachusetts.
  • Qian ZR; Department of Medicine, Division of Hematology-Oncology, University of California, Los Angeles, and the Jonsson Comprehensive Cancer Center, Los Angeles, California.
  • Inamura K; Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
  • Morikawa T; Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
  • Nosho K; Department of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Abril-Rodriguez G; Program in MPE Molecular Pathological Epidemiology, Department of Pathology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
  • Connolly C; Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
  • Escuin-Ordinas H; Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
  • Geybels MS; Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts.
  • Grady WM; Department of Oncologic Pathology, Dana-Farber Cancer Institute, Boston, Massachusetts.
  • Hsu L; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
  • Hu-Lieskovan S; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
  • Huyghe JR; Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts.
  • Kim YJ; Department of Medicine, Division of Hematology-Oncology, University of California, Los Angeles, and the Jonsson Comprehensive Cancer Center, Los Angeles, California.
  • Krystofinski P; Parker Institute for Cancer Immunotherapy, San Francisco, California.
  • Leiserson MDM; Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
  • Montoya DJ; Department of Medicine, Division of Hematology-Oncology, University of California, Los Angeles, and the Jonsson Comprehensive Cancer Center, Los Angeles, California.
  • Nadel BB; Parker Institute for Cancer Immunotherapy, San Francisco, California.
  • Pellegrini M; Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
  • Pritchard CC; Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
  • Puig-Saus C; Department of Medicine, University of Washington School of Medicine, Seattle, Washington.
  • Quist EH; Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
  • Raphael BJ; Department of Medicine, Division of Hematology-Oncology, University of California, Los Angeles, and the Jonsson Comprehensive Cancer Center, Los Angeles, California.
  • Salipante SJ; Parker Institute for Cancer Immunotherapy, San Francisco, California.
  • Shin DS; Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, Washington.
  • Shinbrot E; Department of Medicine, Division of Hematology-Oncology, University of California, Los Angeles, and the Jonsson Comprehensive Cancer Center, Los Angeles, California.
  • Shirts B; Parker Institute for Cancer Immunotherapy, San Francisco, California.
  • Shukla S; Department of Medicine, Division of Hematology-Oncology, University of California, Los Angeles, and the Jonsson Comprehensive Cancer Center, Los Angeles, California.
  • Stanford JL; Parker Institute for Cancer Immunotherapy, San Francisco, California.
  • Sun W; Department of Computer Science and Center for Computational Molecular Biology, Brown University, Providence, Rhode Island.
  • Tsoi J; Department of Molecular, Cell, and Developmental Biology, University of California, Los Angeles, Los Angeles, California.
  • Upfill-Brown A; Department of Molecular, Cell, and Developmental Biology, University of California, Los Angeles, Los Angeles, California.
  • Wheeler DA; Department of Molecular, Cell, and Developmental Biology, University of California, Los Angeles, Los Angeles, California.
  • Wu CJ; Department of Laboratory Medicine, University of Washington, Seattle, Washington.
  • Yu M; Department of Medicine, Division of Hematology-Oncology, University of California, Los Angeles, and the Jonsson Comprehensive Cancer Center, Los Angeles, California.
  • Zaidi SH; Parker Institute for Cancer Immunotherapy, San Francisco, California.
  • Zaretsky JM; Department of Medicine, Division of Hematology-Oncology, University of California, Los Angeles, and the Jonsson Comprehensive Cancer Center, Los Angeles, California.
  • Gabriel SB; Parker Institute for Cancer Immunotherapy, San Francisco, California.
  • Lander ES; Department of Computer Science and Center for Computational Molecular Biology, Brown University, Providence, Rhode Island.
  • Garraway LA; Department of Laboratory Medicine, University of Washington, Seattle, Washington.
  • Hudson TJ; Department of Medicine, Division of Hematology-Oncology, University of California, Los Angeles, and the Jonsson Comprehensive Cancer Center, Los Angeles, California.
  • Fuchs CS; Parker Institute for Cancer Immunotherapy, San Francisco, California.
  • Ribas A; Human Genome Sequencing Center, Baylor College of Medicine, Houston, Texas.
Cancer Discov ; 8(6): 730-749, 2018 06.
Article em En | MEDLINE | ID: mdl-29510987
To understand the genetic drivers of immune recognition and evasion in colorectal cancer, we analyzed 1,211 colorectal cancer primary tumor samples, including 179 classified as microsatellite instability-high (MSI-high). This set includes The Cancer Genome Atlas colorectal cancer cohort of 592 samples, completed and analyzed here. MSI-high, a hypermutated, immunogenic subtype of colorectal cancer, had a high rate of significantly mutated genes in important immune-modulating pathways and in the antigen presentation machinery, including biallelic losses of B2M and HLA genes due to copy-number alterations and copy-neutral loss of heterozygosity. WNT/ß-catenin signaling genes were significantly mutated in all colorectal cancer subtypes, and activated WNT/ß-catenin signaling was correlated with the absence of T-cell infiltration. This large-scale genomic analysis of colorectal cancer demonstrates that MSI-high cases frequently undergo an immunoediting process that provides them with genetic events allowing immune escape despite high mutational load and frequent lymphocytic infiltration and, furthermore, that colorectal cancer tumors have genetic and methylation events associated with activated WNT signaling and T-cell exclusion.Significance: This multi-omic analysis of 1,211 colorectal cancer primary tumors reveals that it should be possible to better monitor resistance in the 15% of cases that respond to immune blockade therapy and also to use WNT signaling inhibitors to reverse immune exclusion in the 85% of cases that currently do not. Cancer Discov; 8(6); 730-49. ©2018 AACR.This article is highlighted in the In This Issue feature, p. 663.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Colorretais / Evasão Tumoral Limite: Humans Idioma: En Revista: Cancer Discov Ano de publicação: 2018 Tipo de documento: Article País de publicação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias Colorretais / Evasão Tumoral Limite: Humans Idioma: En Revista: Cancer Discov Ano de publicação: 2018 Tipo de documento: Article País de publicação: Estados Unidos